AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results
for Anti-Cancer Compound Perifosine at ASCO Meeting
Results showed an overall CBR of 52% which compares favorably withthe activity of mTOR inhibitors QUEBEC CITY, QC, June 04, 2007 /PRNewswire-FirstCall/ -
AEternaZentaris Inc. , a global biopharmaceutical company focused onendocrine therapy and oncology, today announced that its partner,Keryx Biopharmaceuticals presented a poster outlining Phase 1 andPhase 2 results for perifosine, an oral...
AEterna Zentaris' Partner, Spectrum, Discloses Detailed Phase 2
Data for Ozarelix, in BPH at Annual AUA Meeting
Ozarelix improved LUTS symptoms and urine flow over 28-week period QUEBEC CITY, May 23, 2007 /PRNewswire-FirstCall/ -
AEternaZentaris Inc. , a global biopharmaceutical company focused onendocrine therapy and oncology, today announced that its partnerSpectrum Pharmaceuticals presented an abstract outlining detailedPhase 2 results for
AEterna Zentaris' fourth-generation luteinizinghormone-r...
AEterna Zentaris Discloses In Vivo Data for its GHRH Antagonist
JMR-132 at the AACR Annual Meeting in Los Angeles
JMR-132 could provide a new therapeutic approach for the treatmentof early and metastatic breast cancer QUEBEC CITY, April 17, 2007 /PRNewswire-FirstCall/ -
AEternaZentaris Inc. , a global, pure play biopharmaceutical companyfocused on endocrine therapy and oncology, today presented anabstract outlining in vivo data for its growth hormone-releasinghormone (GHRH) antagonist JMR-132 in brea...
AEterna Zentaris Discloses First In Vitro Data for its PI3K
Inhibitors at the AACR Annual Meeting in Los Angeles
Second generation pyridopyrazine-urea derivative compound seriesshow highly selective PI3K-inhibition which could be valuable forcancer treatment QUEBEC, April 16, 2007 /PRNewswire-FirstCall/ -
AEterna ZentarisInc. , a global, pure play biopharmaceutical company focused onendocrine therapy and oncology, today presented an abstractoutlining first in vitro data on its pyridopyrazine derivat...
AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors
and In Vivo Results for a GHRH Antagonist at the AACR Annual
Meeting in Los Angeles
QUEBEC CITY, April 13, 2007 /PRNewswire-FirstCall/ -
AEternaZentaris Inc. , a global, pure play biopharmaceutical companyfocused on endocrine therapy and oncology, today announced that itwill present two abstracts outlining first in vitro data on itsPI3K inhibitors as well as in vivo data on its GHRH antagonist,JMR-132, which both may potentially provide new therapeuticapproaches for the...
More>>